Pfizer (PFE) Looks to Remove 'Black Box' Warning from Chantix

Pfizer (NYSE: PFE) will request that U.S. regulators remove a black box warning from its anti-smoking medication, Chantix.

According to reports Wednesday, the U.S. FDA recently updated labeling on Chantix which includes data from a number of recent studies that found little to no evidence of psychiatric problems or suicidal tendencies in patients taking the tablet.

The FDA will convene a panel in October to review Chantix's risks at the request of Pfizer.

You May Also Be Interested In

• Pfizer (PFE) PT Lowered to $29 at Bernstein SocGen Group
• Spyre Therapeutics launches SPY772 program and Phase 2 trial in HS
• AC Immune gets FDA fast track for Parkinson's drug ACI-7104